Indirect Treatment Comparison of Long-Acting Injectable Cabotegravir as Pre-exposure Prophylaxis When Compared with no Pre-exposure Prophylaxis for HIV Prevention
The ITC of cabotegravir versus no PrEP predicted similar estimates of cabotegravir effectiveness in the HPTN 083 and 084 trials, suggesting a very high level of efficacy despite differences in population, setting, underlying rate of HIV acquisition, and oral TDF/FTC adherence. These estimates support the generalizability of the cabotegravir results from both HPTN trials to other populations and regions than those in which these trials were conducted. Graphical abstract available for this article.
Authors
- Neil Hawkins (ORCID: https://orcid.org/0000-0003-3199-221X)
- Melanie Schroeder (ORCID: https://orcid.org/0000-0003-0338-1331)
- Sarah‐Jane Anderson (ORCID: https://orcid.org/0000-0002-5945-2285)
- L. Benjamin (ORCID: https://orcid.org/0000-0001-7748-0768)
- Paul O’Brien (ORCID: https://orcid.org/0000-0002-6064-8023)
- Eric Julian Manalastas (ORCID: https://orcid.org/0000-0002-6907-4302)
- Juliette C. Thompson (ORCID: https://orcid.org/0000-0001-7646-9460)
Institutions
- ViiV Healthcare (Spain) (ES)
- ViiV Healthcare (United Kingdom) (GB)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-07-05
- DOI
- https://doi.org/10.1007/s40121-025-01172-9
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- ViiV Healthcare